Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized neoadjuvant chemotherapy trial in early breast cancer
2005-000021-32Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2005
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of doxorubicin, pemetrexed, cyclophosphamide and docetaxel in breast cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Pathologic complete response rate in the breast. Started Dec 2005; status: completed.
02
Drugs
doxorubicinpemetrexedcyclophosphamidedocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-000021-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000021-32.